ClinicalTrials.gg
CompletedNCT05686070OCEANIC-STROKEUpdated Nov 20, 2026Results posted

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

A Phase 3 interventional study of Asundexian (BAY2433334) and Placebo in Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke and High-risk Transient Ischemic Attack, sponsored by Bayer. Completed at 741 sites in 37 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12,327
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Ischemic Attack, Transient with a site in United States — 10 open to participants now, 14 under way, 1 of them phase 3. Ischemic Attack, Transient · United States.

Enrollment
2nd of 65
12,327 · median 202
Started
2023
with 2 others
Phase 3
12 of 88
1 open now
Registered
77th of 88
by date
Lead sponsor
4 of 88
Bayer

Among the 88 studies in Ischemic Attack, Transient with a site in United States, this one is the 2nd largest by enrollment of the 65 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 in phase 3, and was the 77th registered.

Ischemic Attack, Transient

330 studies on the registry are indexed under Ischemic Attack, Transient; 72 are open to participants now.

Browse Ischemic Attack, Transient studies →

Open to participants now

10 of the 88 studies in Ischemic Attack, Transient with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Ischemic Attack, Transient studies recruiting now, 38 (68%) set no upper age limit and 6 (11%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Ischemic Attack, Transient with a site in United States, or all of them as a file.
02

Study summary

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had:

  • an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke), or
  • TIA/mini-stroke with a high risk of turning into a stroke (high-risk transient ischemic attack), and who are planned to receive standard of care therapy. Acute ischemic strokes or TIA/mini-stroke result from a blocked or reduced blood flow to a part of the brain. They are caused by blood clots that travel to the brain and block the vessels that supply it. If these blood clots form elsewhere than in the heart, the stroke is called non-cardioembolic. People who already had a non-cardioembolic stroke are more likely to have another stroke. This is why they are treated preventively with an antiplatelet therapy, the current standard of care. Antiplatelet medicines prevent platelets, components of blood clotting, from clumping together.

Anticoagulants are another type of medicine that prevents blood clots from forming by interfering with a process known as coagulation (or blood clotting).

The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care without increasing the risk of bleeding.

The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy. A placebo is a treatment that looks like a medicine but does not have any medicine in it.

Another aim is to compare the occurrence of major bleeding events during the study between the asundexian and the placebo group. Major bleedings have a serious or even life-threatening impact on a person's health.

Dependent on the treatment group, the participants will either take asundexian or placebo once a day for at least 3 months up to 31 months.

Approximately every 3 months during the treatment period, either a phone call or a visit to the study site is scheduled on an alternating basis. In addition, one visit before and up to two visits after the treatment period are planned.

During the study, the study team will:

  • Check vital signs such as blood pressure and heart rate
  • Examine the participants' heart health using an electrocardiogram (ECG)
  • Take blood samples
  • Ask the participants questions about how they are feeling and what adverse events they are having.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.

03

Conditions studied

  • Prevention of Ischemic Stroke
  • Acute Non-cardioembolic Ischemic Stroke
  • High-risk Transient Ischemic Attack
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥ 18 years of age
  • Acute non-cardioembolic stroke or high-risk
  • Systemic or cerebrovascular atherosclerosis or acute non-lacunar infarct

Exclusion criteria

Exclusion Criteria:

  • Ischemic stroke ≤ 7 days before the index event
  • Index stroke following procedures or strokes due to other rare causes
  • History of atrial fibrillation/flutter, left ventricular thrombus, mechanic valve or other cardioembolic source of stroke requiring anticoagulation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12,327 participants (actual)

Study arms

  • Experimental
    Asundexian

    Participants will receive asundexian.

    Drug: Asundexian (BAY2433334)

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Had an Ischemic Stroke

    A participant is counted if a first ischemic stroke occurred after randomization. A time-to-event analysis using a Cox proportional hazards model was used to compare treatment groups over the full follow-up period.

    Time frame: Up to 32 months

  2. Number of Participants Who Had ISTH Major Bleeding

    A participant is counted if a first ISTH (International Society on Thrombosis and Hemostasis) major bleeding event occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

Secondary outcomes

  1. Number of Participants Who Had All Stroke (Ischemic Stroke or Hemorrhagic Stroke)

    A participant is counted if a first stroke (ischemic or hemorrhagic) occurred after randomization during the on-treatment period. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  2. Number of Participants Who Had Composite of Cardiovascular Death, Myocardial Infarction, or Stroke

    A participant is counted if a first occurrence of cardiovascular death, myocardial infarction, or stroke occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  3. Number of Participants Who Had Composite of All-cause Mortality, Myocardial Infarction, or Stroke

    A participant is counted if a first occurrence of all-cause mortality, myocardial infarction, or stroke occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  4. Number of Participants Who Had Disabling Stroke (mRS ≥3 at 90 Days)

    A participant is counted if a first disabling stroke occurred after randomization. Disabling stroke is defined as a stroke of any type associated with a modified Rankin Scale (mRS) score ≥3 at 90 days after the recurrent stroke, or an increase of ≥1 point if the last available mRS before the recurrent stroke was ≥3. Fatal strokes are included. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  5. Number of Participants Who Died (All-cause Mortality)

    A participant is counted if death due to any cause occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  6. Number of Participants Who Had a Transient Ischemic Attack (TIA)

    A participant is counted if a first transient ischemic attack (TIA) occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  7. Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding

    A participant is counted if a first occurrence of ISTH major bleeding or clinically relevant non-major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  8. Number of Participants Who Had ISTH Clinically Relevant Non-major Bleeding

    A participant is counted if a first occurrence of ISTH clinically relevant non-major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  9. Number of Participants Who Had Symptomatic Intracranial Hemorrhage

    A participant is counted if a first symptomatic intracranial hemorrhage occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  10. Number of Participants Who Had Hemorrhagic Stroke

    A participant is counted if a first hemorrhagic stroke occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  11. Number of Participants Who Had Fatal Bleeding

    A participant is counted if a first fatal bleeding event occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  12. Number of Participants Who Had Minor Bleeding

    A participant is counted if a first occurrence of minor bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  13. Number of Participants Who Had Composite of Ischemic Stroke or ISTH Major Bleeding

    A participant is counted if a first occurrence of ischemic stroke or ISTH major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  14. Number of Participants Who Had Composite of Cardiovascular Death, Any Stroke, Myocardial Infarction, or ISTH Major Bleeding

    A participant is counted if a first occurrence of cardiovascular death, any stroke (ischemic or hemorrhagic), myocardial infarction, or ISTH major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  15. Number of Participants Who Had Composite of All-cause Mortality, Disabling Stroke, Fatal Bleeding, or Symptomatic Intracranial Hemorrhage

    A participant is counted if a first occurrence of all-cause mortality, disabling stroke, fatal bleeding, or symptomatic intracranial hemorrhage occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

    Time frame: Up to 32 months

  16. Number of Participants Who Had an Ischemic Stroke in the First 90 Days

    A participant is counted if a first ischemic stroke occurred within 90 days after randomization. Time-to-event analysis was performed using a Cox proportional hazards model restricted to the first 90 days of follow-up to compare treatment groups.

    Time frame: Up to 90 days

07

Results

Posted Nov 20, 2026

Participant flow

12327 participants were randomized. Of those 12254 received the study intervention (6124 asundexian and 6130 placebo). Overall, 12243 completed the study. Of 84 participants who did not complete the study, the primary reason was withdrawal of consent or lost to follow up. The study was conducted at 700 study centers in Asia, Europe, North America and South America, Australia and Israel between 26-Jan-2023 (first participant first visit) and 23-Oct-2025 (last participant last visit).

Participant flow — Overall Study
MilestoneAsundexianPlacebo
Started61626165
Treated61246130
Participants valid for fas analysis61626165
Participants valid for saf analysis61246130
Completed61096134
Not completed5331
Withdrew: Withdrawal by subject3015
Withdrew: Lost to follow-up2316

Outcome measures

PrimaryNumber of Participants Who Had an Ischemic Stroke

A participant is counted if a first ischemic stroke occurred after randomization. A time-to-event analysis using a Cox proportional hazards model was used to compare treatment groups over the full follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had an Ischemic Stroke
ParticipantsAsundexianPlacebo
Number of Participants Who Had an Ischemic Stroke384518
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.739 · 95% CI 0.647 to 0.843
PrimaryNumber of Participants Who Had ISTH Major Bleeding

A participant is counted if a first ISTH (International Society on Thrombosis and Hemostasis) major bleeding event occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had ISTH Major Bleeding
ParticipantsAsundexianPlacebo
Number of Participants Who Had ISTH Major Bleeding117107
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.4587 · Hazard ratio (hr): 1.104 · 95% CI 0.849 to 1.435
SecondaryNumber of Participants Who Had All Stroke (Ischemic Stroke or Hemorrhagic Stroke)

A participant is counted if a first stroke (ischemic or hemorrhagic) occurred after randomization during the on-treatment period. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had All Stroke (Ischemic Stroke or Hemorrhagic Stroke)
ParticipantsAsundexianPlacebo
Number of Participants Who Had All Stroke (Ischemic Stroke or Hemorrhagic Stroke)404545
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 0.738 · 95% CI 0.649 to 0.840
SecondaryNumber of Participants Who Had Composite of Cardiovascular Death, Myocardial Infarction, or Stroke

A participant is counted if a first occurrence of cardiovascular death, myocardial infarction, or stroke occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Composite of Cardiovascular Death, Myocardial Infarction, or Stroke
ParticipantsAsundexianPlacebo
Number of Participants Who Had Composite of Cardiovascular Death, Myocardial Infarction, or Stroke568685
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.0008 · Hazard ratio (hr): 0.827 · 95% CI 0.740 to 0.924
SecondaryNumber of Participants Who Had Composite of All-cause Mortality, Myocardial Infarction, or Stroke

A participant is counted if a first occurrence of all-cause mortality, myocardial infarction, or stroke occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Composite of All-cause Mortality, Myocardial Infarction, or Stroke
ParticipantsAsundexianPlacebo
Number of Participants Who Had Composite of All-cause Mortality, Myocardial Infarction, or Stroke649757
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.0032 · Hazard ratio (hr): 0.855 · 95% CI 0.769 to 0.949
SecondaryNumber of Participants Who Had Disabling Stroke (mRS ≥3 at 90 Days)

A participant is counted if a first disabling stroke occurred after randomization. Disabling stroke is defined as a stroke of any type associated with a modified Rankin Scale (mRS) score ≥3 at 90 days after the recurrent stroke, or an increase of ≥1 point if the last available mRS before the recurrent stroke was ≥3. Fatal strokes are included. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Disabling Stroke (mRS ≥3 at 90 Days)
ParticipantsAsundexianPlacebo
Number of Participants Who Had Disabling Stroke (mRS ≥3 at 90 Days)128185
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.0013 · Hazard ratio (hr): 0.692 · 95% CI 0.553 to 0.867
SecondaryNumber of Participants Who Died (All-cause Mortality)

A participant is counted if death due to any cause occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Died (All-cause Mortality)
ParticipantsAsundexianPlacebo
Number of Participants Who Died (All-cause Mortality)248253
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.8604 · Hazard ratio (hr): 0.984 · 95% CI 0.826 to 1.173
SecondaryNumber of Participants Who Had a Transient Ischemic Attack (TIA)

A participant is counted if a first transient ischemic attack (TIA) occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had a Transient Ischemic Attack (TIA)
ParticipantsAsundexianPlacebo
Number of Participants Who Had a Transient Ischemic Attack (TIA)124145
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.2070 · Hazard ratio (hr): 0.857 · 95% CI 0.675 to 1.090
SecondaryNumber of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding

A participant is counted if a first occurrence of ISTH major bleeding or clinically relevant non-major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding
ParticipantsAsundexianPlacebo
Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding339307
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.1564 · Hazard ratio (hr): 1.118 · 95% CI 0.958 to 1.305
SecondaryNumber of Participants Who Had ISTH Clinically Relevant Non-major Bleeding

A participant is counted if a first occurrence of ISTH clinically relevant non-major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had ISTH Clinically Relevant Non-major Bleeding
ParticipantsAsundexianPlacebo
Number of Participants Who Had ISTH Clinically Relevant Non-major Bleeding231210
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.2644 · Hazard ratio (hr): 1.112 · 95% CI 0.923 to 1.341
SecondaryNumber of Participants Who Had Symptomatic Intracranial Hemorrhage

A participant is counted if a first symptomatic intracranial hemorrhage occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Symptomatic Intracranial Hemorrhage
ParticipantsAsundexianPlacebo
Number of Participants Who Had Symptomatic Intracranial Hemorrhage4136
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.5372 · Hazard ratio (hr): 1.151 · 95% CI 0.736 to 1.801
SecondaryNumber of Participants Who Had Hemorrhagic Stroke

A participant is counted if a first hemorrhagic stroke occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Hemorrhagic Stroke
ParticipantsAsundexianPlacebo
Number of Participants Who Had Hemorrhagic Stroke1320
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.2367 · Hazard ratio (hr): 0.658 · 95% CI 0.327 to 1.323
SecondaryNumber of Participants Who Had Fatal Bleeding

A participant is counted if a first fatal bleeding event occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Fatal Bleeding
ParticipantsAsundexianPlacebo
Number of Participants Who Had Fatal Bleeding148
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.1896 · Hazard ratio (hr): 1.774 · 95% CI 0.744 to 4.230
SecondaryNumber of Participants Who Had Minor Bleeding

A participant is counted if a first occurrence of minor bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Minor Bleeding
ParticipantsAsundexianPlacebo
Number of Participants Who Had Minor Bleeding479512
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.3348 · Hazard ratio (hr): 0.941 · 95% CI 0.830 to 1.065
SecondaryNumber of Participants Who Had Composite of Ischemic Stroke or ISTH Major Bleeding

A participant is counted if a first occurrence of ischemic stroke or ISTH major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Composite of Ischemic Stroke or ISTH Major Bleeding
ParticipantsAsundexianPlacebo
Number of Participants Who Had Composite of Ischemic Stroke or ISTH Major Bleeding430529
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.0019 · Hazard ratio (hr): 0.817 · 95% CI 0.720 to 0.928
SecondaryNumber of Participants Who Had Composite of Cardiovascular Death, Any Stroke, Myocardial Infarction, or ISTH Major Bleeding

A participant is counted if a first occurrence of cardiovascular death, any stroke (ischemic or hemorrhagic), myocardial infarction, or ISTH major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Composite of Cardiovascular Death, Any Stroke, Myocardial Infarction, or ISTH Major Bleeding
ParticipantsAsundexianPlacebo
Number of Participants Who Had Composite of Cardiovascular Death, Any Stroke, Myocardial Infarction, or ISTH Major Bleeding518611
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.0075 · Hazard ratio (hr): 0.853 · 95% CI 0.759 to 0.959
SecondaryNumber of Participants Who Had Composite of All-cause Mortality, Disabling Stroke, Fatal Bleeding, or Symptomatic Intracranial Hemorrhage

A participant is counted if a first occurrence of all-cause mortality, disabling stroke, fatal bleeding, or symptomatic intracranial hemorrhage occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.

Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants Who Had Composite of All-cause Mortality, Disabling Stroke, Fatal Bleeding, or Symptomatic Intracranial Hemorrhage
ParticipantsAsundexianPlacebo
Number of Participants Who Had Composite of All-cause Mortality, Disabling Stroke, Fatal Bleeding, or Symptomatic Intracranial Hemorrhage189234
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.0358 · Hazard ratio (hr): 0.815 · 95% CI 0.673 to 0.987
SecondaryNumber of Participants Who Had an Ischemic Stroke in the First 90 Days

A participant is counted if a first ischemic stroke occurred within 90 days after randomization. Time-to-event analysis was performed using a Cox proportional hazards model restricted to the first 90 days of follow-up to compare treatment groups.

Time frame:
Up to 90 days
Reported as:
Count of participants · Participants
Number of Participants Who Had an Ischemic Stroke in the First 90 Days
ParticipantsAsundexianPlacebo
Number of Participants Who Had an Ischemic Stroke in the First 90 Days183218
Statistical analysis
  • Asundexian vs Placebo · Regression, Cox · p = 0.0805 · Hazard ratio (hr): 0.840 · 95% CI 0.690 to 1.022

Adverse events

Collected over After the first intake of study intervention up to 2 days after the last intake of study intervention, up to 32 months.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asundexian248/6,162 (4%)1,177/6,124 (19.2%)2,600/6,124 (42.5%)
Placebo253/6,165 (4.1%)1,196/6,130 (19.5%)2,667/6,130 (43.5%)
Most frequent serious events
Showing 10 of 1,039
Most frequent serious events
EventAsundexianPlacebo
PneumoniaInfections and infestations54/612465/6130
Urinary tract infectionInfections and infestations36/612422/6130
Atrial fibrillationCardiac disorders31/612433/6130
Acute kidney injuryRenal and urinary disorders26/612432/6130
SyncopeNervous system disorders26/612423/6130
Cardiac failureCardiac disorders24/612412/6130
Carotid artery stenosisNervous system disorders20/612422/6130
COVID-19Infections and infestations20/612416/6130
DeathGeneral disorders and administration site conditions13/612420/6130
FallInjury, poisoning and procedural complications18/612414/6130
Most frequent other events
Showing 10 of 37
Most frequent other events
EventAsundexianPlacebo
ConstipationGastrointestinal disorders346/6124381/6130
Atrial fibrillationCardiac disorders277/6124290/6130
HypertensionVascular disorders232/6124269/6130
Urinary tract infectionInfections and infestations199/6124217/6130
HeadacheNervous system disorders189/6124211/6130
DiarrhoeaGastrointestinal disorders205/6124166/6130
InsomniaPsychiatric disorders177/6124183/6130
NasopharyngitisInfections and infestations176/6124168/6130
DizzinessNervous system disorders175/6124160/6130
ArthralgiaMusculoskeletal and connective tissue disorders159/6124157/6130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AsundexianPlaceboTotal
Mean67.7 ± 10.867.5 ± 10.967.6 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)AsundexianPlaceboTotal
Female206320474110
Male409941188217
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AsundexianPlaceboTotal
Hispanic or Latino5185131031
Not Hispanic or Latino5460545910919
Unknown or Not Reported184193377
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AsundexianPlaceboTotal
American Indian or Alaska Native5574129
Asian172117423463
Native Hawaiian or Other Pacific Islander347
Black or African American143139282
White410540788183
More than one race281644
Unknown or Not Reported107112219
08

Study locations

741 sites
  • Eastern Shore Research Institute, LLC | Fairhope, AL
    Fairhope, Alabama 36532, United States
  • Barrow Neurologic Institute - Petznick Stroke Center
    Phoenix, Arizona 85013, United States
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • Banner - University Medical Center Tucson - Neurology
    Tucson, Arizona 85724, United States
  • University of Arkansas for Medical Sciences - Neurology
    Little Rock, Arkansas 72205, United States
  • Kaiser Permanente Fontana Medical Center
    Fontana, California 92335, United States
  • Long Beach Medical Center - Neurology
    Long Beach, California 90806, United States
  • Kaiser Permanente Los Angeles Medical Center - Neurology
    Los Angeles, California 90027, United States
  • Los Angeles - USC Healthcare Center 2 - Neurology
    Los Angeles, California 90033, United States
  • UCLA NeuroTranslational Research Center
    Los Angeles, California 90095, United States
  • Hoag Memorial Hospital - Center for Research & Education
    Newport Beach, California 92663, United States
  • UCI Medical Center - Neurology
    Orange, California 92868, United States
  • San Francisco VA Health Care System
    San Francisco, California 94121, United States
  • Cottage Health | Santa Barbara Cottage Hospital - Research Department
    Santa Barbara, California 93105, United States
  • The Lundquist Institute - Neurology
    Torrance, California 90502, United States
  • St. Vincent's Medical Center - Neurology Clinic
    Bridgeport, Connecticut 06606, United States
  • Nuvance Health
    Danbury, Connecticut 06810, United States
  • Church Street Research Unit
    New Haven, Connecticut 06519, United States
  • ChristianaCare Health Services | Christiana Hospital - Emergency Medicine Research
    Newark, Delaware 19718, United States
  • HCA Florida JFK Hospital - Neurology
    Atlantis, Florida 33462, United States
  • Delray Medical Center - Neurology
    Boynton Beach, Florida 33472, United States
  • Nova Clinical Research - Blake Medical Center
    Bradenton, Florida 34209, United States
  • BayCare Health System | Morton Plant Hospital - Neuroscience Research department
    Clearwater, Florida 33756, United States
  • UF Health Neuromedicine Hospital
    Gainesville, Florida 32608, United States
  • Baptist Health Research Institute
    Jacksonville, Florida 32207, United States
  • Intercoastal Medical Group | Clinical Research
    Sarasota, Florida 34239, United States
  • USF Health South Tampa Center for Advanced Healthcare - Neurology
    Tampa, Florida 33606, United States
  • BayCare Health System | Saint Joseph's Hospital - Neurology Department
    Tampa, Florida 33607, United States
  • University of Illinois Hospital - Neurology
    Chicago, Illinois 60612, United States
  • The University of Chicago Medical Center - Neurology
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center - Neurology
    Maywood, Illinois 60153, United States
  • Mercyhealth Javon Bea Hospital - Riverside | Neurology Research Department
    Rockford, Illinois 61114, United States
  • HSHS St. John's Hospital - Neurology
    Springfield, Illinois 62769, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Ochsner Medical Center - New Orleans - Neurology
    New Orleans, Louisiana 70121, United States
  • University of Maryland Medical Center - Neurology Care Center
    Baltimore, Maryland 21201, United States
  • Tufts Medical Center - Neurology
    Boston, Massachusetts 02111, United States
  • Henry Ford Hospital - Neurology
    Detroit, Michigan 48202, United States
  • MSU Health Care Neurology & Ophthalmology
    East Lansing, Michigan 48824, United States
  • Trinity Health | Oakland Hospital - Clinical Research Department
    Pontiac, Michigan 48341, United States
  • Minneapolis Clinic of Neurology | Golden Valley, MN
    Golden Valley, Minnesota 55422, United States
  • Mayo Clinic - Rochester - Neurology
    Rochester, Minnesota 55902, United States
  • University Hospital - UMMC - Neurology
    Jackson, Mississippi 39216, United States
  • Saint Luke's Hospital of Kansas City - Neurology
    Kansas City, Missouri 64111, United States
  • Kansas City VA Medical Center - Neurology
    Kansas City, Missouri 64128, United States
  • Barnes-Jewish Hospital - Cardiology
    St Louis, Missouri 63100, United States
  • Mercy Research - St. Louis
    St Louis, Missouri 63141, United States
  • Dartmouth-Hitchcock Medical Center - Neurology
    Lebanon, New Hampshire 03756, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Albany Medical College | Department of Neurology
    Albany, New York 12208, United States
  • SUNY Downstate Health Sciences University - Neurology
    Brooklyn, New York 11203, United States
  • NYU Langone Hospital Brooklyn - Neurology
    Brooklyn, New York 11220, United States
  • Mount Sinai Brooklyn - Neurology
    Brooklyn, New York 11234, United States
  • Trinity Medical Western New York | Trinity Vascular & Endovascular Center - Research Department
    Buffalo, New York 14220, United States
  • Neuroscience Institute at Great Neck
    Great Neck, New York 11021, United States
  • The Neurological Institute - Columbia University Irving Medical Center
    New York, New York 10032, United States
  • Mount Sinai Hospital - Stroke Center
    New York, New York 33756, United States
  • Vassar Brothers Medical Center - Neurologgy
    Poughkeepsie, New York 12601, United States
  • Rochester General Hospital
    Rochester, New York 14621, United States
  • Westchester Medical Center - Neurology
    Valhalla, New York 10595, United States
  • Mission Hospital | Neurology
    Asheville, North Carolina 28801, United States
  • Duke Neurological Disorders Clinic - Clinic 1L
    Durham, North Carolina 27710, United States
  • Guilford Neurologic Research Partners, LLC.
    Greensboro, North Carolina 27405, United States
  • ECU Health Medical Center - Neurology
    Greenville, North Carolina 27834, United States
  • North Carolina Heart & Vascular (Capital Heart)
    Raleigh, North Carolina 27607, United States
  • Novant Health Forsyth Medical Center - Neurology
    Winston-Salem, North Carolina 27103, United States
  • Atrium Health Wake Forest Baptist | Medical Center - Neurology Department
    Winston-Salem, North Carolina 27157, United States
  • Cleveland Clinic - Cardiology
    Cleveland, Ohio 44195, United States
  • Ohio State University Wexner Medical Center - Neurology
    Columbus, Ohio 43210, United States
  • OhioHealth Neuroscience Center at Riverside
    Columbus, Ohio 43214, United States
  • Miami Valley Hospital - Neurology
    Dayton, Ohio 45409, United States
  • Kettering Health Main Campus - Neurology
    Kettering, Ohio 45429, United States
  • Mercy Health - St. Rita's Medical Center - Neurology
    Lima, Ohio 45801, United States
  • ProMedica | ProMedica Toledo Hospital - Neuro/Stroke Research Department
    Toledo, Ohio 43606, United States
  • Mercy Health St. Vincent Medical Center - Neurology
    Toledo, Ohio 43608, United States
  • Mercy Health St. Elizabeth Youngstown Hospital - Neurology
    Youngstown, Ohio 44504, United States
  • OU Health University of Oklahoma Med Center - Neurology
    Oklahoma City, Oklahoma 73104, United States
  • Mercy Hospital Oklahoma City
    Oklahoma City, Oklahoma 73120, United States
  • OHSU Hospital - Neurology
    Portland, Oregon 97239, United States
  • LVH Neurology - 1250 Cedar Crest
    Allentown, Pennsylvania 18103, United States
  • University of Pittsburgh Medical Center, Hamot | Clinical Trials and Research
    Erie, Pennsylvania 16507, United States
  • UPMC Harrisburg - Cardiology
    Harrisburg, Pennsylvania 17101, United States
  • Penn State Milton S. Hershey Medical Center - Neurology
    Hershey, Pennsylvania 17033, United States
  • Lancaster General Health Neuroscience Institute
    Lancaster, Pennsylvania 17601, United States
  • Hospital of the University of Pennsylvania - Neurology
    Philadelphia, Pennsylvania 19104, United States
  • Jefferson Hospital for Neuroscience
    Philadelphia, Pennsylvania 19107, United States
  • Lewis Katz School of Medicine at Temple University | Neurology
    Philadelphia, Pennsylvania 19140, United States
  • Jefferson Einstein Philadelphia Hospital - Neurology
    Philadelphia, Pennsylvania 19141, United States
  • Rhode Island Hospital - Neurology
    Providence, Rhode Island 20903, United States
  • MUSC Health Neurology at Rutledge Tower
    Charleston, South Carolina 29425, United States
  • Prisma Health Greenville Memorial Hospital - Comprehensive Stroke Center
    Greenville, South Carolina 29605, United States
  • Erlanger Neurology
    Chattanooga, Tennessee 37403, United States
  • The University of Tennessee Medical Center - Main Campus - Neurology
    Knoxville, Tennessee 37920, United States
  • Baptist Memorial Hospital East - Cardiology
    Memphis, Tennessee 38120, United States
  • Baylor University Medical Center at Dallas - Neurology
    Dallas, Texas 75204, United States
  • James W. Aston Ambulatory Care Center - Neurology
    Dallas, Texas 75390, United States
  • Doctors Hospital at Renaissance - Neurology
    Edinburg, Texas 78539, United States
  • Texas Health Harris Methodist Hospital - Fort Worth - Neurology
    Fort Worth, Texas 76104, United States
  • Houston Methodist Neurological Institute
    Houston, Texas 77030, United States
  • UTHealth Houston Neurosciences Neurology - Texas Medical Center
    Houston, Texas 77030, United States

Showing the first 100 of 741 sites across 37 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Eikelboom JW, Xu L, Shoamanesh A, Dong Q, Hirano T, Saver JL, Masjuan J, Demchuk AM, Cordonnier C, Bereczki D, Tsivgoulis G, Veltkamp R, Staikov I, Bae HJ, Campbell BCV, Zini A, Lee IH, Kovar M, Mikulik R, Lemmens R, Ferro JM, Robinson T, Christensen H, Ozturk S, Leker RR, Turcani P, Slowik A, Amaya P, Hoo FK, De Marchis GM, Knoflach M, Sylaja PN, Putaala J, Coutinho JM, van der Worp HB, Miglane E, Matijosaitis V, Lindgren AG, Silva GS, Sandset EC, Turuspekova ST, Colorado P, Kasner SE, Keller L, Neumann C, Muehlhofer E, Iversen HK, Silva Y, Ayo-Martin O, Shuaib A, Wang Z, Schulze K, Joundi RA, Sharma M. Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized Trial. Circulation. 2026 Oct 13. doi: 10.1161/CIRCULATIONAHA.126.081836. Online ahead of print. PubMed 42866879 ↗
  • Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, Demchuk AM, Cordonnier C, Bereczki D, Tsivgoulis G, Veltkamp R, Staikov I, Bae HJ, Campbell BCV, Zini A, Lee IH, Kovar M, Mikulik R, Lemmens R, Ferro JM, Robinson T, Christensen H, Ozturk S, Leker RR, Turcani P, Slowik A, Amaya P, Hoo FK, De Marchis GM, Knoflach M, Sylaja PN, Putaala J, Coutinho JM, van der Worp HB, Miglane E, Matijosaitis V, Lindgren AG, Sampaio Silva G, Sandset EC, Turuspekova ST, Amarenco P, Sheth KN, Smith EE, Eikelboom JW, Joundi RA, Schulze K, Xu L, Heenan L, Colorado P, Keller L, Muehlhofer E, Neumann C, Mundl H, Shoamanesh A; OCEANIC-STROKE Investigators. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026 Apr 16;394(15):1467-1479. doi: 10.1056/NEJMoa2513880. PubMed 41985132 ↗
  • Sharma M, Dong Q, Hirano T, Kasner SE, Saver J, Masjuan J, Demchuk AM, Cordonnier C, Bereczki D, Tsivgoulis G, Veltkamp R, Staikov I, Bae HJ, Campbell BCV, Zini A, Lee IH, Ameriso S, Kovar M, Mikulik R, Lemmens R, Ferro JM, Robinson T, Christensen H, Ozturk S, Leker RR, Turcani P, Slowik A, Amaya P, Hoo FK, De Marchis GM, Knoflach M, Sylaja PN, Putaala J, Coutinho JM, Worp HBV, Miglane E, Matijosaitis V, Lindgren AG, Silva GS, Sandset EC, Turuspekova ST, Joundi RA, Schulze K, Shestakovska O, Gilbride J, Bangdiwala SI, Xu L, Muehlhofer E, Colorado P, Mundl H, Keller L, Shoamanesh A. Rationale, design and baseline characteristics of participants in the OCEANIC-STROKE trial of FXIa inhibition for secondary stroke prevention. Eur Stroke J. 2026 Jan 1;11(1):aakaf017. doi: 10.1093/esj/aakaf017. PubMed 41614533 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Oct 2025, 32 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 14 phase 3 interventional studies under Ischemic Attack, Transient, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 51. This study's 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2023
First posted
Jan 17, 2023
StartActual
Jan 26, 2023
Primary completionActual
Oct 23, 2025
CompletionActual
Oct 23, 2025
Results first posted
Nov 20, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 20, 2026
Sites
301 sites added, 301 sites removed
Show 301 added (27 France, 25 Spain, 22 Taiwan, 17 Bulgaria, 17 Greece, 17 Japan, 16 Canada, 12 Turkey (Türkiye), 10 Netherlands, 10 United Kingdom, 9 Malaysia, 9 Portugal, 8 Denmark, 8 Sweden, 7 Austria, 7 Colombia, 6 Brazil, 6 Czechia, 6 India, 6 Norway, 6 South Korea, 5 United States, 5 China, 5 Finland, 5 Germany, 5 Israel, 5 Latvia, 4 Hungary, 4 Switzerland, 3 Argentina, 3 Australia, 3 Kazakhstan, 2 Slovakia, 1 Belgium)
  • Church Street Research Unit · New Haven, United States
  • Vassar Brothers Medical Center - Neurologgy · Poughkeepsie, United States
  • Westchester Medical Center - Neurology · Valhalla, United States
  • Cleveland Clinic - Cardiology · Cleveland, United States
  • Miami Valley Hospital - Neurology · Dayton, United States
  • Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno" · Ciudad Autónoma de Buenos Aire, Argentina
  • Sanatorio Allende | Departamento de Investigación Clínica · Córdoba, Argentina
  • San Bernardo Hospital | Neurology Department · Salta, Argentina
  • The Canberra Hospital - Neurology Department · Garran, Australia
  • Nepean Hospital · Kingswood, Australia
  • The Alfred Hospital · Prahran, Australia
  • Barmherzige Brueder Wien | Abt. fuer Neurologie · Vienna, Austria
  • Medizinische Universität Innsbruck · Vienna, Austria
  • AKH Wien | Univ. Klinik fuer Neurologie · Vienna, Austria
  • Universitaetsklinikum Graz | Abteilung für Neurologie · Vienna, Austria
  • Klinik Ottakring | Neurologische Abteilung · Vienna, Austria
  • Klinik Floridsdorf | Abt. f. Neurologie · Vienna, Austria
  • Landesklinikum Moedling | Abteilung für Neurologie · Linz, Austria
  • CHC MontLégia Neurology Department · Liège, Belgium
  • Hospital Moinhos de Vento-Centro Clínico · Uberlândia, Brazil
  • L'Dor - Instituto de Ensino e Pesquisa · Rio de Janeiro, Brazil
  • Unifesp/Epm · São Paulo, Brazil
  • Science Valley Research Institute · São Paulo, Brazil
  • Sociedade Matonense de Benemerência · São Paulo, Brazil
  • Centro de Pesquisas do Hospital Bahia · São Paulo, Brazil
  • Multiprofile Hospital for Active Treatment Haskovo AD | Department of Nervous Diseases · Haskovo, Bulgaria
  • Multispecialty Hospital for Active Treatment St. Ivan Rilski - 2003 | Neurological Department · Dupnitsa, Bulgaria
  • Multiprofile Hospital for Active Treatment Pazardzhik · Pazardzhik, Bulgaria
  • Military Medical Academy | Multiprofile Hospital for Active Treatment Pleven - Neurology Department · Pleven, Bulgaria
  • University Multiprofile Hospital for Active Treatment Dr Georgi Stranski Pleven | Department of Neurology · Pleven, Bulgaria
  • …and 271 more on the registry record
Show 301 removed
  • Yale University | School of Medicine - Department of Neurology · New Haven, United States
  • Westchester Medical Center · Hawthorne, United States
  • Vassar Brothers Medical Center · Poughkeepsie, United States
  • Cleveland Clinic - Neurology · Cleveland, United States
  • Wright State University | Boonshoft School of Medicine - WSU and Premier Health Clinical Trials Research Alliance · Dayton, United States
  • Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno" · Buenos Aires, Argentina
  • Sanatorio Allende | Departamento de Investigación Clínica · Córdoba, Argentina
  • San Bernardo Hospital | Neurology Department · Salta, Argentina
  • The Canberra Hospital · Garran, Australia
  • Nepean Hospital · Sydney, Australia
  • The Alfred Hospital · Melbourne, Australia
  • Landesklinikum Moedling | Abteilung für Neurologie · Mödling, Austria
  • Universitaetsklinikum Graz | Abteilung für Neurologie · Graz, Austria
  • Medizinische Universität Innsbruck · Innsbruck, Austria
  • Barmherzige Brueder Wien | Abt. fuer Neurologie · Vienna, Austria
  • AKH Wien | Univ. Klinik fuer Neurologie · Vienna, Austria
  • Klinik Ottakring | Neurologische Abteilung · Vienna, Austria
  • Klinik Floridsdorf | Abt. f. Neurologie · Vienna, Austria
  • CHC MontLégia Neurology Department · Liège, Belgium
  • Centro de Pesquisas do Hospital Bahia · Salvador, Brazil
  • Hospital Moinhos de Vento-Centro Clínico · Porto Alegre, Brazil
  • Sociedade Matonense de Benemerência · Matão, Brazil
  • L'Dor - Instituto de Ensino e Pesquisa · Rio de Janeiro, Brazil
  • Science Valley Research Institute · São Paulo, Brazil
  • Unifesp/Epm · São Paulo, Brazil
  • Multispecialty Hospital for Active Treatment St. Ivan Rilski - 2003 | Neurological Department · Dupnitsa, Bulgaria
  • Multiprofile Hospital for Active Treatment Haskovo AD | Department of Nervous Diseases · Haskovo, Bulgaria
  • Multiprofile Hospital for Active Treatment Pazardzhik · Pazardzhik, Bulgaria
  • Military Medical Academy | Multiprofile Hospital for Active Treatment Pleven - Neurology Department · Pleven, Bulgaria
  • University Multiprofile Hospital for Active Treatment Dr Georgi Stranski Pleven | Department of Neurology · Pleven, Bulgaria
  • …and 271 more on the registry record
Nov 20, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedTime to first occurrenceNumber of Participants Who Had ISTH major bleedingMajor BleedingTime frame: Up to 31 months → Up to 32 months
  • ChangedBefore Time to first occurrence of ischemic strokeNow Number of Participants Who Had an Ischemic StrokeTime frame: Up to 31 months → Up to 32 months
Nov 20, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42866879 ↗
Nov 20, 2026
Secondary outcomes
12 edited, 4 added, 4 removed
What changed in the outcomes
  • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of CV deathCardiovascular Death, MIMyocardial Infarction, or strokeStrokeTime frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of allAll-cause mortalityMortality, MIMyocardial Infarction, or strokeStrokeTime frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of disabling strokeParticipants Who Had Disabling Stroke (mRS ≥3 at 90 daysDays)Time frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of allParticipants Who Died (All-cause mortalityMortality)Time frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of transient ischemic attackParticipants Who Had a Transient Ischemic Attack (TIA)Time frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of compositeParticipants With Composite of ISTH majorMajor or clinically relevant nonClinically Relevant Non-major bleedingBleedingTime frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of Participants Who Had ISTH clinically relevant nonClinically Relevant Non-major bleedingBleedingTime frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of symptomatic intracranial hemorrhageParticipants Who Had Symptomatic Intracranial HemorrhageTime frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of ischemic strokeIschemic Stroke or ISTH major bleedingMajor BleedingTime frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of CV deathCardiovascular Death, all strokeAny Stroke, MIMyocardial Infarction, or ISTH major bleedingMajor BleedingTime frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of allAll-cause mortalityMortality, disabling strokeDisabling Stroke, fatal bleedingFatal Bleeding, symptomatic intracranial hemorrhageor Symptomatic Intracranial HemorrhageTime frame: Up to 31 months → Up to 32 months
  • EditedTime to first occurrenceNumber of ischemic strokeParticipants Who Had an Ischemic Stroke in the firstFirst 90 daysDaysTime frame: Up to 31 months → Up to 90 days
  • AddedNumber of Participants Who Had All Stroke (Ischemic Stroke or Hemorrhagic Stroke)Time frame: Up to 32 months
  • AddedNumber of Participants Who Had Hemorrhagic StrokeTime frame: Up to 32 months
  • AddedNumber of Participants Who Had Fatal BleedingTime frame: Up to 32 months
  • AddedNumber of Participants Who Had Minor BleedingTime frame: Up to 32 months
  • RemovedTime to first occurrence of all strokes (ischemic and hemorrhagic)Time frame: Up to 31 months
  • RemovedTime to first occurrence of hemorrhagic strokeTime frame: Up to 31 months
  • RemovedTime to first occurrence of fatal bleedingTime frame: Up to 31 months
  • RemovedTime to first occurrence of minor bleedingTime frame: Up to 31 months
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42866879 ↗
    301 sites added, 301 sites removed
    Show 301 added (27 France, 25 Spain, 22 Taiwan, 17 Bulgaria, 17 Greece, 17 Japan, 16 Canada, 12 Turkey (Türkiye), 10 Netherlands, 10 United Kingdom, 9 Malaysia, 9 Portugal, 8 Denmark, 8 Sweden, 7 Austria, 7 Colombia, 6 Brazil, 6 Czechia, 6 India, 6 Norway, 6 South Korea, 5 United States, 5 China, 5 Finland, 5 Germany, 5 Israel, 5 Latvia, 4 Hungary, 4 Switzerland, 3 Argentina, 3 Australia, 3 Kazakhstan, 2 Slovakia, 1 Belgium)
    • Church Street Research Unit · New Haven, United States
    • Vassar Brothers Medical Center - Neurologgy · Poughkeepsie, United States
    • Westchester Medical Center - Neurology · Valhalla, United States
    • Cleveland Clinic - Cardiology · Cleveland, United States
    • Miami Valley Hospital - Neurology · Dayton, United States
    • Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno" · Ciudad Autónoma de Buenos Aire, Argentina
    • Sanatorio Allende | Departamento de Investigación Clínica · Córdoba, Argentina
    • San Bernardo Hospital | Neurology Department · Salta, Argentina
    • The Canberra Hospital - Neurology Department · Garran, Australia
    • Nepean Hospital · Kingswood, Australia
    • The Alfred Hospital · Prahran, Australia
    • Barmherzige Brueder Wien | Abt. fuer Neurologie · Vienna, Austria
    • Medizinische Universität Innsbruck · Vienna, Austria
    • AKH Wien | Univ. Klinik fuer Neurologie · Vienna, Austria
    • Universitaetsklinikum Graz | Abteilung für Neurologie · Vienna, Austria
    • Klinik Ottakring | Neurologische Abteilung · Vienna, Austria
    • Klinik Floridsdorf | Abt. f. Neurologie · Vienna, Austria
    • Landesklinikum Moedling | Abteilung für Neurologie · Linz, Austria
    • CHC MontLégia Neurology Department · Liège, Belgium
    • Hospital Moinhos de Vento-Centro Clínico · Uberlândia, Brazil
    • L'Dor - Instituto de Ensino e Pesquisa · Rio de Janeiro, Brazil
    • Unifesp/Epm · São Paulo, Brazil
    • Science Valley Research Institute · São Paulo, Brazil
    • Sociedade Matonense de Benemerência · São Paulo, Brazil
    • Centro de Pesquisas do Hospital Bahia · São Paulo, Brazil
    • Multiprofile Hospital for Active Treatment Haskovo AD | Department of Nervous Diseases · Haskovo, Bulgaria
    • Multispecialty Hospital for Active Treatment St. Ivan Rilski - 2003 | Neurological Department · Dupnitsa, Bulgaria
    • Multiprofile Hospital for Active Treatment Pazardzhik · Pazardzhik, Bulgaria
    • Military Medical Academy | Multiprofile Hospital for Active Treatment Pleven - Neurology Department · Pleven, Bulgaria
    • University Multiprofile Hospital for Active Treatment Dr Georgi Stranski Pleven | Department of Neurology · Pleven, Bulgaria
    • …and 271 more on the registry record
    Show 301 removed
    • Yale University | School of Medicine - Department of Neurology · New Haven, United States
    • Westchester Medical Center · Hawthorne, United States
    • Vassar Brothers Medical Center · Poughkeepsie, United States
    • Cleveland Clinic - Neurology · Cleveland, United States
    • Wright State University | Boonshoft School of Medicine - WSU and Premier Health Clinical Trials Research Alliance · Dayton, United States
    • Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno" · Buenos Aires, Argentina
    • Sanatorio Allende | Departamento de Investigación Clínica · Córdoba, Argentina
    • San Bernardo Hospital | Neurology Department · Salta, Argentina
    • The Canberra Hospital · Garran, Australia
    • Nepean Hospital · Sydney, Australia
    • The Alfred Hospital · Melbourne, Australia
    • Landesklinikum Moedling | Abteilung für Neurologie · Mödling, Austria
    • Universitaetsklinikum Graz | Abteilung für Neurologie · Graz, Austria
    • Medizinische Universität Innsbruck · Innsbruck, Austria
    • Barmherzige Brueder Wien | Abt. fuer Neurologie · Vienna, Austria
    • AKH Wien | Univ. Klinik fuer Neurologie · Vienna, Austria
    • Klinik Ottakring | Neurologische Abteilung · Vienna, Austria
    • Klinik Floridsdorf | Abt. f. Neurologie · Vienna, Austria
    • CHC MontLégia Neurology Department · Liège, Belgium
    • Centro de Pesquisas do Hospital Bahia · Salvador, Brazil
    • Hospital Moinhos de Vento-Centro Clínico · Porto Alegre, Brazil
    • Sociedade Matonense de Benemerência · Matão, Brazil
    • L'Dor - Instituto de Ensino e Pesquisa · Rio de Janeiro, Brazil
    • Science Valley Research Institute · São Paulo, Brazil
    • Unifesp/Epm · São Paulo, Brazil
    • Multispecialty Hospital for Active Treatment St. Ivan Rilski - 2003 | Neurological Department · Dupnitsa, Bulgaria
    • Multiprofile Hospital for Active Treatment Haskovo AD | Department of Nervous Diseases · Haskovo, Bulgaria
    • Multiprofile Hospital for Active Treatment Pazardzhik · Pazardzhik, Bulgaria
    • Military Medical Academy | Multiprofile Hospital for Active Treatment Pleven - Neurology Department · Pleven, Bulgaria
    • University Multiprofile Hospital for Active Treatment Dr Georgi Stranski Pleven | Department of Neurology · Pleven, Bulgaria
    • …and 271 more on the registry record
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedTime to first occurrenceNumber of Participants Who Had ISTH major bleedingMajor BleedingTime frame: Up to 31 months → Up to 32 months
    • ChangedBefore Time to first occurrence of ischemic strokeNow Number of Participants Who Had an Ischemic StrokeTime frame: Up to 31 months → Up to 32 months
    Secondary outcomes 12 edited, 4 added, 4 removed
    What changed in the outcomes
    • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of CV deathCardiovascular Death, MIMyocardial Infarction, or strokeStrokeTime frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of allAll-cause mortalityMortality, MIMyocardial Infarction, or strokeStrokeTime frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of disabling strokeParticipants Who Had Disabling Stroke (mRS ≥3 at 90 daysDays)Time frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of allParticipants Who Died (All-cause mortalityMortality)Time frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of transient ischemic attackParticipants Who Had a Transient Ischemic Attack (TIA)Time frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of compositeParticipants With Composite of ISTH majorMajor or clinically relevant nonClinically Relevant Non-major bleedingBleedingTime frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of Participants Who Had ISTH clinically relevant nonClinically Relevant Non-major bleedingBleedingTime frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of symptomatic intracranial hemorrhageParticipants Who Had Symptomatic Intracranial HemorrhageTime frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of ischemic strokeIschemic Stroke or ISTH major bleedingMajor BleedingTime frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of CV deathCardiovascular Death, all strokeAny Stroke, MIMyocardial Infarction, or ISTH major bleedingMajor BleedingTime frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of compositeParticipants Who Had Composite of allAll-cause mortalityMortality, disabling strokeDisabling Stroke, fatal bleedingFatal Bleeding, symptomatic intracranial hemorrhageor Symptomatic Intracranial HemorrhageTime frame: Up to 31 months → Up to 32 months
    • EditedTime to first occurrenceNumber of ischemic strokeParticipants Who Had an Ischemic Stroke in the firstFirst 90 daysDaysTime frame: Up to 31 months → Up to 90 days
    • AddedNumber of Participants Who Had All Stroke (Ischemic Stroke or Hemorrhagic Stroke)Time frame: Up to 32 months
    • AddedNumber of Participants Who Had Hemorrhagic StrokeTime frame: Up to 32 months
    • AddedNumber of Participants Who Had Fatal BleedingTime frame: Up to 32 months
    • AddedNumber of Participants Who Had Minor BleedingTime frame: Up to 32 months
    • RemovedTime to first occurrence of all strokes (ischemic and hemorrhagic)Time frame: Up to 31 months
    • RemovedTime to first occurrence of hemorrhagic strokeTime frame: Up to 31 months
    • RemovedTime to first occurrence of fatal bleedingTime frame: Up to 31 months
    • RemovedTime to first occurrence of minor bleedingTime frame: Up to 31 months
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05686070
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 17, 2023
Start date
Jan 26, 2023
Primary completion
Oct 23, 2025
Completion
Oct 23, 2025
Results posted
Nov 20, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asundexian

Start the discussion